Rates of preterm delivery, lower-than-normal birth weight, and maternal disease flares are higher among pregnant women with ANCA-associated vasculitis (AAV) than in the general population, according to a review study. Despite this, “most pregnancies resulted in healthy newborns and manageable, non-life-threatening flares of AAV,” the researchers wrote, suggesting that “pregnancy…
Standard therapies used to ANCA-associated vasculitis (AAV), like cyclophosphamide or Rituxan (rituximab), appear to be of benefit in patients who are pregnant, a literature review suggests. The study, “Successful treatment outcomes in pregnant patients with ANCA‐associated vasculitides: A systematic review of literature,” was published in the International Journal…
Women who develop ANCA-associated vasculitis while pregnant are more likely to suffer maternal and fetal complications, according to a systematic literature review. To ensure the best possible outcome, investigators recommend these patients be closely monitored by a multidisciplinary team of healthcare providers. The systematic review, “De novo…
Pregnant women who develop ANCA-associated vasculitis (AAV) may safely receive Rituxan (rituximab) and corticosteroids, a case study suggests. However, this is the first study describing Rituxan’s use in pregnant women with vasculitis, and researchers say more evidence of its safety and effectiveness is needed. The study, “…
Microscopic polyangiitis with kidney manifestations, a subtype of ANCA-associated vasculitis, can develop in women after a pregnancy, a case report from Japan suggests. The study, “Microscopic polyangiitis necrotizing glomerulonephritis associated with pregnancy: case with a 20-year clinical course and review of the literature,” appeared in the journal…
Get regular updates to your inbox.